Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.46 |
| ▸ | CA2 | P00918 | 11/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 7/20 | 0.41 |
| ▸ | CA9 | Q16790 | 7/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26045685 | 0.92 | TDP1 (0.46) | CA1CA2TDP1MAOAMAOB | |
| SCHEMBL26046033 | 0.92 | TDP1 (0.46) | CA1CA2TDP1MAOAMAOB | |
| SCHEMBL25835268 | 0.92 | TDP1 (0.43) | CA1CA2TDP1MAOAMAOB | |
| SCHEMBL16328105 | 0.91 | TDP1 (0.44) | CA1CA2TDP1MAOAMAOB | |
| SCHEMBL9063285 | 0.91 | TDP1 (0.51) | CA1CA2TDP1MAOAMAOB | |
| SCHEMBL26032381 | 0.90 | TDP1 (0.42) | CA1CA2TDP1MAOAMAOB | |
| SCHEMBL26032853 | 0.90 | TDP1 (0.42) | CA1CA2TDP1MAOAMAOB | |
| SCHEMBL21071324 | 0.90 | TDP1 (0.50) | CA1CA2TDP1MAOAMAOB | |
| SCHEMBL26044735 | 0.89 | TDP1 (0.48) | CA1CA2TDP1MAOAMAOB | |
| SCHEMBL222081 | 0.88 | TDP1 (0.50) | CA1CA2TDP1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | CA1 4862/4885CA2 4620/4885TDP1 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.